President & CEO

Mr. Cohen is the founding CEO of 20/20 GeneSystems.   In that capacity he has lead the company to raise over $5 million in equity investments, procure over $7 million in funding from government and corporate sources, and forge license and distribution agreements with several Fortune 500 companies.  He also spearheaded the launch of 20/20’s highly successful BioCheck product which is used by over 500 emergency response organizations worldwide. 

Active in public policy initiatives on behalf of the biotechnology industry, Mr. Cohen conceived of and helped bring about the passage of the Maryland Biotechnology Investment Tax Credit which is widely deemed to be the most effective investment incentive in the U.S.  He has testified before several Congressional committees and is the architect of the Innovative Technologies Investment Incentive Act which was introduced by Rep. Chris Van Hollen in 2011.   That bill was adopted by the Democratic leadership as part of their Make it in America legislative package.   Cohen is a founding director of the Small Biotechnology Business Coalition. 

Before starting 20/20 Mr. Cohen was patent and general counsel for two publically traded companies: Ventana Medical Systems Inc. (acquired by Roche diagnostics, 2008) and Oncor Inc. Mr. Cohen is a registered patent attorney with over 18 years experience in biotechnology patents and licensing matters.   Cohen has a Master of Science Degree in Biotechnology from Johns Hopkins University and a law degree from the American University.